AstraZeneca unveils new CFO as sales slump continues
This article was originally published in Scrip
AstraZeneca has reported an ongoing slide in sales and profits in the third quarter as recent losses of exclusivity in key products continue to bite. The pharma giant also announced that it has found a replacement for CFO Simon Lowth, who leaves AstraZeneca today (31 October).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.